参考文献
［1］Chen W，Zheng R，Baade P D，et al.Cancer statistics in China，2015.CA Cancer J Clin，2016，66（2）：115-132.
［2］Tuveson D，Clevers H.Cancer modeling meets human organoid technology.Science，2019，364（6444）：952-955.
［3］Lau H C H，Kranenburg O，Xiao H，et al.Organoid models of gastrointestinal cancers in basic and translational research.Nat Rev Gastroenterol Hepatol，2020，17（4）：203-222.
［4］Sato T，Vries R G，Snippert H J，et al.Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche.Nature，2009，459（7244）：262-265.
［5］Sato T，Stange D E，Ferrante M，et al.Long-term expansion of epithelial organoids from human colon，adenoma，adenocarcinoma，and Barrett's epithelium.Gastroenterology，2011，141（5）：1762-1772.
［6］Van De Wetering M，Francies H E，Francis J M，et al.Prospective derivation of a living organoid biobank of colorectal cancer patients.Cell，2015，161（4）：933-945.
［7］Robinson D，Van Allen E M，Wu Y M，et al.Integrative clinical genomics of advanced prostate cancer.Cell，2015，161（5）：1215-1228.
［8］Pauli C，Moch H，Rubin M A.Establishment of a living biobank：Improved guidance of precision cancer care with in vitro and in vivo cancer models.Pathologe，2017，38（Suppl 2）：160-168.
［9］Sachs N，De Ligt J，Kopper O，et al.A living biobank of breast cancer organoids captures disease heterogeneity.Cell，2018，172（1-2）：373-86.e10.
［10］Hill S J，Decker B，Roberts E A，et al.Prediction of DNA repair inhibitor response in short-term patient-derived ovarian cancer organoids.Cancer Discov，2018，8（11）：1404-1421.
［11］Vlachogiannis G，Hedayat S，Vatsiou A，et al.Patient-derived organoids model treatment response of metastatic gastrointestinal cancers.Science，2018，359（6378）：920-926.
［12］Yan H H N，Siu H C，Law S，et al.A comprehensive human gastric cancer organoid biobank captures tumor subtype heterogeneity and enables therapeutic screening.Cell Stem Cell，2018，23（6）：882-897.
［13］Sachs N，Papaspyropoulos A，Zomer-Van Ommen D D，et al.Long-term expanding human airway organoids for disease modeling.Embo j，2019，38（4）.
［14］Driehuis E，Kolders S，Spelier S，et al.Oral mucosal organoids as a potential platform for personalized cancer therapy.Cancer Discov，2019，9（7）：852-871.
［15］Kopper O，De Witte C J，Lõhmussaar K，et al.An organoid platform for ovarian cancer captures intra-and interpatient heterogeneity.Nat Med，2019，25（5）：838-849.
［16］Ooft S N，Weeber F，Dijkstra K K，et al.Patient-derived organoids can predict response to chemotherapy in metastatic colorectal cancer patients.Sci Transl Med，2019，11（513）.
［17］Ganesh K，Wu C，O'rourke K P，et al.A rectal cancer organoid platform to study individual responses to chemoradiation.Nat Med，2019，25（10）：1607-1614.
［18］Yao Y，Xu X，Yang L，et al.Patient-derived organoids predict chemoradiation responses of locally advanced rectal cancer.Cell Stem Cell，2020，26（1）：17-26.
［19］Calandrini C，Schutgens F，Oka R，et al.An organoid biobank for childhood kidney cancers that captures disease and tissue heterogeneity.Nat Commun，2020，11（1）：1310.
［20］De Witte C J，Espejo Valle-Inclan J，Hami N，et al.Patient-derived ovarian cancer organoids mimic clinical response and exhibit heterogeneous inter-and intrapatient drug responses.Cell Rep，2020，31（11）：107762.
［21］Kawasaki K，Toshimitsu K，Matano M，et al.An organoid biobank of neuroendocrine neoplasms enables genotype-phenotype mapping.Cell，2020，183（5）：1420-1435.
［22］Chalabi M，Fanchi L F，Dijkstra K K，et al.Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers.Nat Med，2020，26（4）：566-576.
［23］Lõhmussaar K，Oka R，Espejo Valle-Inclan J，et al.Patient-derived organoids model cervical tissue dynamics and viral oncogenesis in cervical cancer.Cell Stem Cell，2021，28（8）：1380-1396.
［24］Jacob F，Salinas R D，Zhang D Y，et al.A patient-derived glioblastoma organoid model and biobank recapitulates inter-and intra-tumoral heterogeneity.Cell，2020，180（1）：188-204.
［25］Herpers B，Eppink B，James M I，et al.Functional patient-derived organoid screenings identify MCLA-158 as a therapeutic EGFR×LGR5 bispecific antibody with efficacy in epithelial tumors.Nat Cancer，2022，3（4）：418-436.
［26］Shi X，Li Y，Yuan Q，et al.Integrated profiling of human pancreatic cancer organoids reveals chromatin accessibility features associated with drug sensitivity.Nat Commun，2022，13（1）：2169.
［27］Ding S，Hsu C，Wang Z，et al.Patient-derived micro-organospheres enable clinical precision oncology.Cell Stem Cell，2022，29（6）：905-917.
［28］He G W，Lin L，Demartino J，et al.Optimized human intestinal organoid model reveals interleukin-22-dependency of paneth cell formation.Cell Stem Cell，2022，29（12）：1718-1720.
［29］Artegiani B，Hendriks D，Beumer J，et al.Fast and efficient generation of knock-in human organoids using homology-independent CRISPR-Cas9 precision genome editing.Nat Cell Biol，2020，22（3）：321-331.
［30］Driehuis E，Kretzschmar K，Clevers H.Establishment of patient-derived cancer organoids for drug-screening applications.Nat Protoc，2020，15（10）：3380-3409.
［31］Zhang L，Mo S，Hu X，et al.Establishment and identification of organoids from human circulating colorectal cancer cells.Clin Transl Med，2020，10（8）：e247.
［32］De Angelis M L，Francescangeli F，Nicolazzo C，et al.An organoid model of colorectal circulating tumor cells with stem cell features，hybrid EMT state and distinctive therapy response profile.J Exp Clin Cancer Res，2022，41（1）：86.
［33］Kim M，Mun H，Sung C O，et al.Patient-derived lung cancer organoids as in vitro cancer models for therapeutic screening.Nat Commun，2019，10（1）：3991.
［34］Neal J T，Li X，Zhu J，et al.Organoid modeling of the tumor immune microenvironment.Cell，2018，175（7）：1972-1988.
［35］Xie B Y，Wu A W.Organoid culture of isolated cells from patient-derived tissues with colorectal cancer.Chin Med J（Engl），2016，129（20）：2469-2475.
［36］Lee S H，Hu W，Matulay J T，et al.Tumor evolution and drug response in patient-derived organoid models of bladder Cancer.Cell，2018，173（2）：515-528.
［37］中国抗癌协会肿瘤多学科诊疗专业委员会.肿瘤类器官诊治平台的质量控制标准中国专家共识（2022年版）.中国癌症杂志，2022，32（7）：657-668.
［38］Flensburg C，Sargeant T，Oshlack A，et al.Super Freq：Integrated mutation detection and clonal tracking in cancer.PLoS Comput Biol，2020，16（2）：e1007603.
［39］Tiriac H，Belleau P，Engle D D，et al.Organoid profiling identifies common responders to chemotherapy in pancreatic cancer.Cancer Discov，2018，8（9）：1112-1129.
［40］Seino T，Kawasaki S，Shimokawa M，et al.Human pancreatic tumor organoids reveal loss of stem cell niche factor dependence during disease progression.Cell Stem Cell，2018，22（3）：454-467.
［41］Roerink S F，Sasaki N，Lee-Six H，et al.Intra-tumour diversification in colorectal cancer at the single-cell level.Nature，2018，556（7702）：457-462.
［42］Sung H，Ferlay J，Siegel R L，et al.Global Cancer Statistics 2020：GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.CA Cancer J Clin，2021，71（3）：209-249.
［43］Drost J，Van Jaarsveld R H，Ponsioen B，et al.Sequential cancer mutations in cultured human intestinal stem cells.Nature，2015，521（7550）：43-47.
［44］Comprehensive molecular characterization of human colon and rectal cancer.Nature，2012，487（7407）：330-337.
［45］Roper J，Tammela T，Akkad A，et al.Colonoscopy-based colorectal cancer modeling in mice with CRISPR-Cas9 genome editing and organoid transplantation.Nat Protoc，2018，13（2）：217-234.
［46］Lannagan T R M，Lee Y K，Wang T，et al.Genetic editing of colonic organoids provides a molecularly distinct and orthotopic preclinical model of serrated carcinogenesis.Gut，2019，68（4）：684-692.
［47］Roper J，Tammela T，Cetinbas N M，et al.In vivo genome editing and organoid transplantation models of colorectal cancer and metastasis.Nat Biotechnol，2017，35（6）：569-576.
［48］Roulis M，Kaklamanos A，Schernthanner M，et al.Paracrine orchestration of intestinal tumorigenesis by a mesenchymal niche.Nature，2020，580（7804）：524-529.
［49］Mo S，Tang P，Luo W，et al.Patient-derived organoids from colorectal cancer with paired liver metastasis reveal tumor heterogeneity and predict response to chemotherapy.Adv Sci（Weinh），2022，9（31）：e2204097.
［50］Ooft S N，Weeber F，Schipper L，et al.Prospective experimental treatment of colorectal cancer patients based on organoid drug responses.ESMO Open，2021，6（3）：100103.
［51］Sato T，Clevers H.SnapShot：Growing organoids from stem cells.Cell，2015，161（7）：1700.
［52］Merker S R，Weitz J，Stange D E.Gastrointestinal organoids：How they gut it out.Dev Biol，2016，420（2）：239-250.
［53］Drost J，Clevers H.Organoids in cancer research.Nat Rev Cancer，2018，18（7）：407-418.
［54］Wallaschek N，Niklas C，Pompaiah M，et al.Establishing pure cancer organoid cultures：Identification，selection and verification of cancer phenotypes and genotypes.J Mol Biol，2019，431（15）：2884-2893.
［55］Nanki K，Toshimitsu K，Takano A，et al.Divergent routes toward Wnt and R-spondin niche independency during human gastric carcinogenesis.Cell，2018，174（4）：856-869.
［56］Steele N G，Chakrabarti J，Wang J，et al.An organoid-based preclinical model of human gastric cancer.Cell Mol Gastroenterol Hepatol，2019，7（1）：161-184.
［57］Kijima T，Nakagawa H，Shimonosono M，et al.Three-dimensional organoids reveal therapy resistance of esophageal and oropharyngeal squamous cell carcinoma cells.Cell Mol Gastroenterol Hepatol，2019，7（1）：73-91.
［58］Li X，Francies H E，Secrier M，et al.Organoid cultures recapitulate esophageal adenocarcinoma heterogeneity providing a model for clonality studies and precision therapeutics.Nat Commun，2018，9（1）：2983.
［59］Liu X，Cheng Y，Abraham J M，et al.Modeling Wnt signaling by CRISPR-Cas9 genome editing recapitulates neoplasia in human Barrett epithelial organoids.Cancer Lett，2018，436：109-118.(https://www.daowen.com)
［60］Boj S F，Hwang C I，Baker L A，et al.Organoid models of human and mouse ductal pancreatic cancer.Cell，2015，160（1-2）：324-338.
［61］Lee J，Snyder E R，Liu Y，et al.Reconstituting development of pancreatic intraepithelial neoplasia from primary human pancreas duct cells.Nat Commun，2017，8：14686.
［62］Broutier L，Mastrogiovanni G，Verstegen M M，et al.Human primary liver cancer-derived organoid cultures for disease modeling and drug screening.Nat Med，2017，23（12）：1424-1435.
［63］Nuciforo S，Fofana I，Matter M S，et al.Organoid models of human liver cancers derived from tumor needle biopsies.Cell Rep，2018，24（5）：1363-1376.
［64］Sun L，Wang Y，Cen J，et al.Modelling liver cancer initiation with organoids derived from directly reprogrammed human hepatocytes.Nat Cell Biol，2019，21（8）：1015-1026.
［65］Chan L H，Zhou L，Ng K Y，et al.PRMT6 regulates RAS/RAF binding and MEK/ERKMediated cancer stemness activities in Hepatocellular carcinoma through CRAF methylation.Cell Rep，2018，25（3）：690-701.
［66］Nie Y Z，Zheng Y W，Miyakawa K，et al.Recapitulation of hepatitis B virus-host interactions in liver organoids from human induced pluripotent stem cells.EBio Medicine，2018，35：114-123.
［67］Votanopoulos K I，Mazzocchi A，Sivakumar H，et al.Appendiceal cancer patient-specific tumor organoid model for predicting chemotherapy efficacy prior to initiation of treatment：a feasibility study.Ann Surg Oncol，2019，26（1）：139-147.
［68］Yuan B，Zhao X，Wang X，et al.Patient-derived organoids for personalized gallbladder cancer modelling and drug screening.Clin Transl Med，2022，12（1）：e678.
［69］Saito Y，Muramatsu T，Kanai Y，et al.Establishment of Patient-Derived Organoids and Drug Screening for Biliary Tract Carcinoma.Cell Rep，2019，27（4）：1265-1276.
［70］Dost A F M，Moye A L，Vedaie M，et al.Organoids model transcriptional hallmarks of oncogenic KRASactivation in lung epithelial progenitor cells.Cell Stem Cell，2020，27（4）：663-678.
［71］Hu Y，Sui X，Song F，et al.Lung cancer organoids analyzed on microwell arrays predict drug responses of patients within a week.Nat Commun，2021，12（1）：2581.
［72］Walsh A J，Cook R S，Sanders M E，et al.Quantitative optical imaging of primary tumor organoid metabolism predicts drug response in breast cancer.Cancer Res，2014，74（18）：5184-5194.
［73］Campaner E，Zannini A，Santorsola M，et al.Breast cancer organoids model patient-specific response to drug treatment.Cancers（Basel），2020，12（12）.
［74］Arun G，Diermeier S，Akerman M，et al.Differentiation of mammary tumors and reduction in metastasis upon Malat1 lncRNA loss.Genes Dev，2016，30（1）：34-51.
［75］Corda G，Sala G，Lattanzio R，et al.Functional and prognostic significance of the genomic amplification of frizzled 6（FZD6）in breast cancer.J Pathol，2017，241（3）：350-361.
［76］Nolan E，Vaillant F，Branstetter D，et al.RANK ligand as a potential target for breast cancer prevention in BRCA1-mutation carriers.Nat Med，2016，22（8）：933-939.
［77］Cellurale C，Girnius N，Jiang F，et al.Role of JNK in mammary gland development and breast cancer.Cancer Res，2012，72（2）：472-481.
［78］Ebrahimi N，Nasr Esfahani A，Samizade S，et al.The potential application of organoids in breast cancer research and treatment.Hum Genet，2022，141（2）：193-208.
［79］Jelovac D，Armstrong D K.Recent progress in the diagnosis and treatment of ovarian cancer.CA Cancer J Clin，2011，61（3）：183-203.
［80］Liu H D，Xia B R，Jin M Z，et al.Organoid of ovarian cancer：genomic analysis and drug screening.Clin Transl Oncol，2020，22（8）：1240-1251.
［81］Girda E，Huang E C，Leiserowitz G S，et al.The use of endometrial cancer patient-derived organoid culture for drug sensitivity testing is feasible.Int J Gynecol Cancer，2017，27（8）：1701-1707.
［82］Wu Y L，Li J Q，Sulaiman Z，et al.Optimization of endometrial cancer organoids establishment by cancer-associated fibroblasts.Neoplasma，2022，69（4）：877-885.
［83］Kazama A，Anraku T，Kuroki H，et al.Development of patient-derived tumor organoids and a drug testing model for renal cell carcinoma.Oncol Rep，2021，46（4）.
［84］Grassi L，Alfonsi R，Francescangeli F，et al.Organoids as a new model for improving regenerative medicine and cancer personalized therapy in renal diseases.Cell Death Dis，2019，10（3）：201.
［85］Schutgens F，Rookmaaker M B，Margaritis T，et al.Tubuloids derived from human adult kidney and urine for personalized disease modeling.Nat Biotechnol，2019，37（3）：303-313.
［86］Wang B，Xue Y，Zhai W.Integration of tumor microenvironment in patient-derived organoid models help define precision medicine of renal cell carcinoma.Front Immunol，2022，13：902060.
［87］Vilgelm A E，Bergdorf K，Wolf M，et al.Fine-needle aspiration-based patient-derived cancer organoids.iScience，2020，23（8）：101408.
［88］Ao Z，Cai H，Wu Z，et al.Evaluation of cancer immunotherapy using mini-tumor chips.Theranostics，2022，12（8）：3628-3636.
［89］Meijer R P.Urothelial cancer organoids：a tool for bladder cancer research.Pathologe，2021，42（Suppl 2）：165-169.
［90］Melzer M K，Zehe V，Zengerling F，et al.Organoids as a milestone on the way to personalized treatment of urothelial carcinoma：a systematic review.Urologie，2022，61（7）：745-752.
［91］Mullenders J，De Jongh E，Brousali A，et al.Mouse and human urothelial cancer organoids：A tool for bladder cancer research.Proc Natl Acad Sci U S A，2019，116（10）：4567-4574.
［92］Kim E，Choi S，Kang B，et al.Creation of bladder assembloids mimicking tissue regeneration and cancer.Nature，2020，588（7839）：664-669.
［93］Yu L，Li Z，Mei H，et al.Patient-derived organoids of bladder cancer recapitulate antigen expression profiles and serve as a personal evaluation model for CAR-T cells in vitro.Clin Transl Immunology，2021，10（2）：e1248.
［94］Gao D，Vela I，Sboner A，et al.Organoid cultures derived from patients with advanced prostate cancer.Cell，2014，159（1）：176-187.
［95］Puca L，Bareja R，Prandi D，et al.Patient derived organoids to model rare prostate cancer phenotypes.Nat Commun，2018，9（1）：2404.
［96］Beshiri M L，Tice C M，Tran C，et al.A PDX/organoid biobank of advanced prostate cancers captures genomic and phenotypic heterogeneity for disease modeling and therapeutic screening.Clin Cancer Res，2018，24（17）：4332-4345.
［97］Van Hemelryk A，Mout L，Erkens-Schulze S，et al.Modeling prostate cancer treatment responses in the organoid era：3D environment impacts drug testing.Biomolecules，2021，11（11）.
［98］Allemani C，Matsuda T，Di Carlo V，et al.Global surveillance of trends in cancer survival 2000-14（CONCORD-3）：analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries.Lancet，2018，391（10125）：1023-1075.
［99］Xu X，Li L，Luo L，et al.Opportunities and challenges of glioma organoids.Cell Commun Signal，2021，19（1）：102.
［100］Linkous A，Balamatsias D，Snuderl M，et al.Modeling patient-derived glioblastoma with cerebral organoids.Cell Rep，2019，26（12）：3203-3211.
［101］Papaioannou M D，Sangster K，Sajid R S，et al.Cerebral organoids：emerging ex vivo humanoid models of glioblastoma.Acta Neuropathol Commun，2020，8（1）：209.
［102］Lv T，Shen L，Xu X，et al.Patient-derived tumor organoids predict responses to irinotecanbased neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer.Int J Cancer，2023，152（3）：524-535.
［103］Narasimhan V，Wright J A，Churchill M，et al.Medium-throughput drug screening of patientderived organoids from colorectal peritoneal metastases to direct personalized therapy.Clin Cancer Res，2020，26（14）：3662-3670.
［104］Dijkstra K K，Cattaneo C M，Weeber F，et al.Generation of tumor-reactive T cells by coculture of peripheral blood lymphocytes and tumor organoids.Cell，2018，174（6）：1586-1598.
［
105］Farshadi E A，Chang J，Sampadi B，et al.Organoids derived from neoadjuvant FOLFIRINOX patients recapitulate therapy resistance in pancreatic ductal adenocarcinoma.Clin Cancer Res，2021，27（23）：6602-6612.
［106］Wu M H，Huang S B，Lee G B.Microfluidic cell culture systems for drug research.Lab Chip，2010，10（8）：939-956.
［107］Xie H，Appelt J W，Jenkins R W.Going with the flow：Modeling the tumor microenvironment using microfluidic technology.Cancers（Basel），2021，13（23）.
［108］Deng J，Wang E S，Jenkins R W，et al.CDK4/6 inhibition augments antitumor immunity by enhancing T-cell activation.Cancer Discov，2018，8（2）：216-233.
［109］Jenkins R W，Aref A R，Lizotte P H，et al.Ex vivo profiling of PD-1 blockade using organotypic tumor spheroids.Cancer Discov，2018，8（2）：196-215.
［110］W M K，Derieppe M，Van Den Ham F，et al.Neuroblastoma and DIPG organoid coculture system for personalized assessment of novel anticancer immunotherapies.J Pers Med，2021，11（9）.
［111］Sui Q，Liu D，Jiang W，et al.Dickkopf 1 impairs the tumor response to PD-1 blockade by inactivating CD8+T cells in deficient mismatch repair colorectal cancer.J Immunother Cancer，2021，9（3）.
［112］Yuki K，Cheng N，Nakano M，et al.Organoid models of tumor immunology.Trends Immunol，2020，41（8）：652-664.
［113］Bhat S M，Badiger V A，Vasishta S，et al.3D tumor angiogenesis models：recent advances and challenges.J Cancer Res Clin Oncol，2021，147（12）：3477-3494.
［114］Zhao X，Xu Z，Xiao L，et al.Review on the vascularization of organoids and organoids-on-achip.Front Bioeng Biotechnol，2021，9：637048.
［115］Nashimoto Y，Hayashi T，Kunita I，et al.Integrating perfusable vascular networks with a three-dimensional tissue in a microfluidic device.Integr Biol（Camb），2017，9（6）：506-518.
［116］Lancaster M A.Brain organoids get vascularized.Nat Biotechnol，2018，36（5）：407-408.